Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas
Trial Parameters
Brief Summary
This clinical trial studies advanced MR imaging techniques in measuring early response of standard treatment may become predictors of long-term treatment response in patients with newly diagnosed glioblastomas.
Eligibility Criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of newly diagnosed glioblastoma * Patients must have measurable disease, defined as evident tumors with gadolinium enhancement on MRI that is measurable in at least one diameter * Life expectancy of greater than 3 months * Patients scheduled for standard therapy (6 weeks radiation treatment (RT) \~ 60 Gy, plus temozolomide 75 mg/m\^2 during 6 week RT, and followed routine monthly temozolomide therapy) * Ability to understand and the willingness to sign a written informed consent document; all patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines Exclusion Criteria: * Patients who underwent complete resection * Patients with no evidence of measurable disease after surgery * Patients who have had chemotherapy or radiotherapy * Patients who have any type of